Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.
Mark T. Fleming, MD
Advertisement
Articles by Mark T. Fleming, MD
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.
Advertisement
Latest Updated Articles
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate CancerPublished: March 5th 2025 | Updated:
Episode 2: Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate CancerPublished: March 5th 2025 | Updated:
- Episode 14: Multidisciplinary Care Insights Across World GU 2025
Published: September 18th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
2
Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC
3
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
4
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer
5
